KYUNG DONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,480 KRW | -0.15% |
|
+1.25% | -1.97% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 183B 135M | Sales 2023 | 163B 120M | Capitalization | 179B 133M |
|---|---|---|---|---|---|
| Net income 2022 | 12.16B 9M | Net income 2023 | -20.71B -15.32M | EV / Sales 2022 | 1.07 x |
| Net cash position 2022 | 18.26B 13.51M | Net cash position 2023 | 16.7B 12.36M | EV / Sales 2023 | 1 x |
| P/E ratio 2022 |
17.6
x | P/E ratio 2023 |
-8.66
x | Employees | 385 |
| Yield 2022 |
5.08% | Yield 2023 |
6.05% | Free-Float | 43.63% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.15% | ||
| 1 week | +1.25% | ||
| Current month | +1.73% | ||
| 1 month | +3.68% | ||
| 3 months | +0.78% | ||
| 6 months | -0.92% | ||
| Current year | -1.97% |
1 week
6 330.00
6 550.00
1 month
6 250.006 760.00
Current year
6 120.006 760.00
1 year
6 120.008 420.00
3 years
6 120.0017 650.00
5 years
5 830.0018 300.00
10 years
5 830.0018 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gi-Sung Ryu
CEO | Chief Executive Officer | 41 | 06-10-31 |
Kyung-Hoon Kim
DFI | Director of Finance/CFO | 51 | - |
Jae-Bok Lee
AUD | Comptroller/Controller/Auditor | 84 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gi-Sung Ryu
CEO | Chief Executive Officer | 41 | 06-10-31 |
Soon-Bo Lee
BRD | Director/Board Member | 79 | - |
Sang-Woo Lee
BRD | Director/Board Member | 43 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 6,480 | -0.15% | 19,961 |
| 24-05-16 | 6,490 | +1.25% | 42,110 |
| 24-05-14 | 6,410 | -0.16% | 19,630 |
| 24-05-13 | 6,420 | +0.31% | 40,958 |
| 24-05-10 | 6,400 | +0.63% | 22,146 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.97% | 130M | |
| +21.63% | 44.11B | |
| +23.03% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.56B | |
| +60.18% | 12.7B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
- Stock Market
- Equities
- A011040 Stock
